Double Blinded Drug Discovery (DBD2): A New Protected Open Innovation Model

Posted by

SELECTBIO

Melvin Reichman, President & CEO, LIMR Chemical Genomics Center

Abstract
The Lankenau Chemical Genomics Center (LCGC) is a totally new, automated molecular diversity depot (patents issued and pending) offering university networks access to 'diversity-clustered smart-snapshots (DCSS) from big pharmas' vast chemical collections, under a symbiotically transformative, public-private consortium for drug discovery research.